Oncology and Therapy最新文献

{"title":"Clinical and Dosimetric Predictors of Early Onset Postradiation Hypothyroidism in Patients with Head and Neck Malignancies: A Logistic Regression Analysis.","authors":"Ahmad Ameri, Zohreh Azma, Khashayar Fattah, Fereshteh Talebi, Pooya Ameri, Nazanin Rahnama, Mansour Lesan, Sanaz Poshtmahi, Farahnaz Rahimi, Marjan Mirsalehi, Farzad Taghizadeh-Hesary","doi":"10.1007/s40487-025-00338-2","DOIUrl":"10.1007/s40487-025-00338-2","url":null,"abstract":"<p><strong>Introduction: </strong>Hypothyroidism commonly occurs as a side effect following radiotherapy for head and neck malignancies, yet limited information exists to predict the risk of postradiation hypothyroidism. This study aims to investigate the clinical and dosimetric factors that may predict early onset postradiation hypothyroidism (EO-PRH).</p><p><strong>Methods: </strong>A retrospective study was conducted on patients with head and neck cancer treated between 2018 and 2021, with a minimum follow-up duration of 12 months. The thyroid gland was contoured on computed tomography (CT) scans, and dose-volume histograms were analyzed, incorporating thyroid volume and V_5-60 into the analysis. Logistic regression and receiver operating characteristic (ROC) analysis were performed to identify predictors and assess the model's predictive value.</p><p><strong>Results: </strong>Among the 84 eligible patients, 17 (20.2%) developed hypothyroidism within 1 year. The percentage of thyroid volume receiving 30 Gy (V₃₀) emerged as the sole significant dosimetric predictor of EO-PRH (odds ratio [OR] 1.02, 95% confidence interval [95% CI] 1.005-1.05, p = 0.03). Univariable analysis revealed significant differences in cancer histopathology, primary tumor site, V_15,30, and VS_15,30 (the volume of the thyroid spared from radiation doses 15 Gy and 30 Gy) between the hypothyroid and euthyroid groups (p < 0.10). Multivariable analysis identified the primary cancer site (OR 9.09, 95% CI 1.59-100) and V₃₀ (OR 1.26, 95% CI 1.007-1.76) as independent significant variables predicting EO-PRH. The predictive model incorporating cancer histopathology, primary tumor site, V_15,30, and VS_15,30 effectively predicted postradiation thyroid dysfunction (area under the receiver operating characteristic curve [AUC-ROC] 0.84, 95% CI 0.73-0.95, p < 0.001).</p><p><strong>Conclusions: </strong>V₃₀ could serve as a dosimetric predictor of hypothyroidism following neck radiotherapy. This study underscores that a predictive model encompassing cancer type and site, along with V_15,30 and VS_15,30, can effectively predict EO-PRH.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":"447-463"},"PeriodicalIF":3.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12129879/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144023578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase I Study of Sorafenib Combined with Gemcitabine and Carboplatin in Patients with Advanced Solid Tumors.","authors":"Daphne W M Voogd, Merel J J Lucassen, Ruud van der Noll, Sybrand W J Zielhuis, David Boss, Jos H Beijnen, Hilde Rosing, Matthijs Tibben, Alwin D R Huitema, Jan H M Schellens, Neeltje Steeghs","doi":"10.1007/s40487-025-00340-8","DOIUrl":"10.1007/s40487-025-00340-8","url":null,"abstract":"<p><strong>Introduction: </strong>A combination of targeted anticancer drugs with cytotoxic therapy can potentially overcome multidrug resistance. The multi-target kinase inhibitor sorafenib demonstrates synergistic activity when combined with chemotherapeutics in preclinical models. This phase I trial aimed to assess safety, tolerability, efficacy, and pharmacokinetics of sorafenib with gemcitabine and carboplatin.</p><p><strong>Methods: </strong>This single-center, open-label, dose-escalation and dose-expansion study included patients with advanced solid tumors considered for palliative treatment with gemcitabine and carboplatin. The maximum tolerated dose (MTD) was determined using a classic 3 + 3 dose-escalation design. Antitumor activity was evaluated every two treatment cycles.</p><p><strong>Results: </strong>In total, 45 patients received treatment. Of the patients, 49% (n = 22) were male, and median age was 58 years [range: 27-72 years]. After dose-escalation, sorafenib 400 mg once daily (q.d.) on days 1-21, gemcitabine 500 mg/m² on day 1 and day 8 (D1D8), and carboplatin AUC3 on day 1 (D1) every 3 weeks (Q3W) were established as the MTD. Grade 4 treatment-related toxicities, all hematological, were seen in 22% of the patients. Frequently observed grade 3 adverse events were neutropenia (33%), thrombocytopenia (31%), leukopenia (16%), and fatigue (13%). Dose reductions were required in 33% of the patients across all dose levels. Disease control rate after 18 weeks was 50%. Median progression-free survival and overall survival were 5.4 months and 10.1 months, respectively.</p><p><strong>Conclusions: </strong>A recommended phase 2 regimen of sorafenib 400 mg q.d. combined with gemcitabine 500 mg/m² D1D8 and carboplatin AUC3 D1, Q3W showed a manageable toxicity profile. This combination could provide an effective treatment option for patients in whom other therapies have failed since antitumor activity was seen across heavily pretreated tumor types. Alternative dosing regimens should be studied to optimize the dosing schedule.</p><p><strong>Trial registration: </strong>EudraCT: 2007-004129-75.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":"465-483"},"PeriodicalIF":3.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12130374/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144037525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-Effectiveness of Elranatamab Versus Current Therapies for the Management of Patients with Triple-Class Exposed, Relapsed and Refractory Multiple Myeloma, Including Other Bispecific and Physician's Choice of Treatment in Spain.","authors":"Cristina Encinas, Virginia Lozano, Patrick Hlavacek, Julia Llinares, Sofía Toribio-Castelló, David Carcedo, Jordi Asís-Montalt, Joaquín Martínez-López","doi":"10.1007/s40487-025-00333-7","DOIUrl":"10.1007/s40487-025-00333-7","url":null,"abstract":"<p><strong>Introduction: </strong>Elranatamab is a bispecific anti-B-cell maturation antigen (BCMA) and -CD3 antibody recently approved in Spain for the treatment of adult patients with triple-class exposed relapsed and refractory multiple myeloma (TCE-RRMM). The objective of this analysis was to assess its cost-effectiveness versus teclistamab, another recently approved bispecific antibody, and a treatment basket representing current physician's choice of treatment (PCT).</p><p><strong>Methods: </strong>A partitioned survival model with three health states was adapted to the Spanish setting. Efficacy data were obtained from the MagnetisMM-3 clinical trial for elranatamab, and from a matching adjusted indirect comparison (MAIC) of elranatamab versus teclistamab and PCT. Utility values were gathered from the MagnetisMM-3 trial for each health state. Only direct costs (2024 €) were considered. Deterministic and probabilistic sensitivity analyses were conducted to assess the uncertainty of the variables and determine the robustness of the results.</p><p><strong>Results: </strong>Treatment with elranatamab is cost-effective compared to PCT, generating 0.92 additional quality-adjusted life years (QALYs) and an additional €17,860 over a lifetime horizon, yielding an incremental cost-effectiveness ratio (ICER) of €24,754/QALY. Elranatamab is dominant (less costly, more effective) versus teclistamab, providing 0.60 additional QALYs and generating cost savings (- €101,026). Sensitivity analyses confirmed the direction of the base case results.</p><p><strong>Conclusion: </strong>Elranatamab is a cost-effective treatment versus PCT and dominant over teclistamab for the treatment of adult patients with TCE-RRMM in the Spanish setting.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":"381-395"},"PeriodicalIF":3.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12130381/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Management and Outcomes of Immune-Related Adverse Events During Treatment with Immune Checkpoint Inhibitor Therapies in Melanoma and Renal Cell Carcinoma: A UK Real-World Evidence Study.","authors":"Anna Olsson-Brown, Ankit Jain, Ricky Frazer, David Farrugia, Judith Carser, John Houghton, Ruth D Lewis, Simon D'Mello, Gabrielle Emanuel","doi":"10.1007/s40487-025-00349-z","DOIUrl":"https://doi.org/10.1007/s40487-025-00349-z","url":null,"abstract":"<p><strong>Introduction: </strong>Immune checkpoint inhibitor (ICI) therapy, although effective in treating patients with a variety of advanced malignancies, can result in potentially severe or even fatal immune-related adverse events (irAEs). This study aimed to generate real-world evidence on irAE characteristics, clinical management and clinical outcomes among patients with advanced (unresectable or metastatic) malignant melanoma (a/mMM) or advanced renal cell carcinoma (aRCC) treated with nivolumab (NIVO) and/or ipilimumab (IPI) in the UK.</p><p><strong>Methods: </strong>This was a multi-centre, retrospective cohort study of adult patients with a/mMM or aRCC, who received NIVO and/or IPI at one of five specialist treatment centres in the UK between 1 January 2016 and 31 March 2020. The incidence and grading of irAEs were described, as well as time to irAE onset, the management of irAEs and overall survival (OS).</p><p><strong>Results: </strong>In total, 199 patients were included in the study: 162 with a/mMM and 37 with aRCC. The majority of patients in both a/mMM (75.3%) and aRCC (62.2%) cohorts reported any irAE, while 45.9% and 30.4% in the a/mMM and aRCC cohorts reported grade 3 or 4 irAEs, respectively. Colitis/diarrhoea, skin reactions and hepatitis were most frequently reported, and the predominant treatment prescribed for any irAE was corticosteroids only. Analysis indicated a positive association between the development of an irAE and longer OS.</p><p><strong>Conclusions: </strong>Findings from this study support current literature, provide further insights into the characteristics and clinical management of irAEs and support an association between the development of an irAE and improved OS in these patient groups.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144192318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunotherapy in Triple-Negative Breast Cancer.","authors":"Elisa Tiberi, Alessandro Parisi, Mirco Pistelli, Agnese Savini, Federica Galassi, Chiara Reschini, Debora Quintavalle, Riccardo Napoleoni, Carlo Ferrari, Rossana Berardi","doi":"10.1007/s40487-025-00346-2","DOIUrl":"https://doi.org/10.1007/s40487-025-00346-2","url":null,"abstract":"<p><p>Currently, immunotherapy has led to a paradigmatic shift in the treatment of many cancer types, including triple-negative breast cancer. Immunotherapy increases the efficacy of the immune system in treating cancer, with a durable effect due to immunologic memory. The PD-1 inhibitor, pembrolizumab, combined with neoadjuvant chemotherapy, improved event-free survival and is a new standard of care for patients with high-risk, early stage triple-negative breast cancer (TNBC), regardless of tumor PD-L1 expression. For metastatic TNBC, pembrolizumab combined with chemotherapy is a new standard of care for first-line therapy for PD-L1⁺ metastatic TNBC, and it improves overall survival. The PD-L1 inhibitor, atezolizumab, combined with nab-paclitaxel, is also approved for first-line treatment of metastatic PD-L1⁺ TNBC. The aim of this review is to examine the existing evidence and ongoing studies on immunotherapy in patients with early stage and metastatic triple-negative breast cancer (TNBC), including new combination strategies with several drugs, such as chemotherapy, targeted therapy, or radiation and to discuss immune checkpoint inhibitor (ICI) applications and the possibility of emerging strategies in different TNBC stages.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144143131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"When Neck Dissection is Not Indicated in the Treatment of the Clinically Node-Negative Head and Neck Squamous Cell Carcinoma.","authors":"Marc Hamoir, Remco de Bree, Primoz Strojan, Nabil F Saba, Alfio Ferlito","doi":"10.1007/s40487-025-00348-0","DOIUrl":"https://doi.org/10.1007/s40487-025-00348-0","url":null,"abstract":"","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144129239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management and Clinical Outcomes of Patients with Advanced Ovarian Cancer in Routine Clinical Practice in Spain: The OVOC Study.","authors":"Maria Quindós-Varela, Diego Soto de Prado-Otero, Alejandro Gallego, Yolanda García, Eva Guerra, Purificación Estévez-García, Maria Pilar Barretina-Ginesta, Pilar Borraz, Antonio González-Martín, María Jesús Rubio","doi":"10.1007/s40487-025-00347-1","DOIUrl":"https://doi.org/10.1007/s40487-025-00347-1","url":null,"abstract":"<p><strong>Introduction: </strong>The OVOC study was carried out to evaluate the management and clinical evolution of patients with advanced ovarian cancer (AOC) in routine clinical practice in Spain.</p><p><strong>Methods: </strong>A retrospective study was made in women diagnosed with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (FIGO IIIB-IV) who had received at least one line of treatment between 2013 and 2016, before the establishment of poly ADP ribose polymerase (PARP) inhibitors as first-line treatment.</p><p><strong>Results: </strong>A total of 400 patients (median age: 61.7 years; FIGO IIIC: 60.0%; high-grade serous carcinoma: 75.0%) received a median of two therapy lines. Primary and interval debulking surgery was performed in 37.0% and 54.3% of the patients. Germline BRCA1 and BRCA2 mutations were found in 16.2% and 12.0% of the patients. The median progression-free survival (PFS) from the start of the first-/second-/third-line of treatment was 14.2/8.7/4.5 months. The median treatment-free interval (TFI) to the start of the second line was 9.9 months. The median overall survival (OS) was 42.6 months. At first relapse, 65.9% of the patients were platinum-sensitive and 34.1% platinum-resistant. Biologic therapies were administered in 25.2% of the platinum-sensitive and 16.2% of the platinum-resistant patients. Patients harboring BRCA mutations had a lower risk of progression/relapse after the first (BRCA1 and BRCA2 mutation versus native: p < 0.0001) and second line (BRCA1 and BRCA2 mutation versus native: p = 0.021 and p = 0.037, respectively). Patients with BRCA2 mutations had a lower mortality risk than those without (p = 0.015). The median PFS was significantly higher in patients receiving targeted therapy in the first (17.4 versus 11.6 months; p = 0.039) and second line (11.1 versus 7.8 months; p < 0.001).</p><p><strong>Conclusion: </strong>This study provides real-world data on therapeutic management and outcomes in AOC patients in Spain. A longer PFS was achieved in patients receiving targeted therapies. BRCA1/2 mutations were a favorable prognostic factor for PFS and BRCA2 mutation for OS.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144112277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Cost-Effectiveness Analysis for Avelumab as a First-Line Maintenance Treatment of Advanced Urothelial Carcinoma in the Netherlands.","authors":"David Smalbrugge, Tim Walsteijn, Jeantine de Feijter, Britt Suelmann, Mairead Kearney, Agnes Benedict, Venediktos Kapetanakis, Sophie van Beekhuizen","doi":"10.1007/s40487-025-00345-3","DOIUrl":"https://doi.org/10.1007/s40487-025-00345-3","url":null,"abstract":"<p><strong>Introduction: </strong>Advanced or metastatic urothelial carcinoma (UC) is an incurable disease with a high disease burden and a poor prognosis. Avelumab as first-line (1L) maintenance treatment is an innovative therapy option for patients with advanced or metastatic UC that has not progressed after 4-6 cycles of 1L platinum-based chemotherapy. This study aimed to assess the cost-effectiveness of avelumab maintenance treatment plus best supportive care (BSC) versus BSC alone from a Dutch societal perspective.</p><p><strong>Methods: </strong>A partitioned survival model was developed incorporating JAVELIN Bladder 100 trial data to inform overall and progression-free survival, adverse events incidence, and health-state utilities. Costs for drugs, healthcare resource use, adverse events, and indirect costs were obtained from national databases, the Dutch costing manual, and published literature. Assumptions were validated by clinical experts. An incremental cost-effectiveness ratio (ICER) was determined using lifetime incremental costs and quality-adjusted life years (QALY).</p><p><strong>Results: </strong>Avelumab 1L maintenance treatment plus BSC was estimated to have €48,186 discounted incremental costs and 0.63 discounted incremental QALYs versus BSC alone, leading to a base-case ICER of €76,450, supported by consistent scenario and sensitivity analyses.</p><p><strong>Conclusion: </strong>Avelumab 1L maintenance treatment is likely to be a cost-effective treatment in advanced or metastatic urothelial carcinoma in the Netherlands.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144086799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Experience and Care Pathway of Patients with Lung Cancer: An Online International Survey.","authors":"Pauline Frank, Julie Laurent, Lorraine Dallas, Pasquale Varriale, Andrew Ciupek","doi":"10.1007/s40487-024-00314-2","DOIUrl":"10.1007/s40487-024-00314-2","url":null,"abstract":"<p><strong>Introduction: </strong>This research sought to identify trends in the patient with lung cancer (LC) care pathway, experiences, and needs, across geographies and healthcare settings.</p><p><strong>Methods: </strong>Patients living with LC for more than 18 years in nine countries completed an online survey covering these domains-demographic, disease, treatment, and patient preferences for information and support services. Recruitment was primarily from patient with LC communities on online platforms.</p><p><strong>Results: </strong>A total of 1000 patients with LC completed the survey across Europe (49%), North America (29%), and Asia (22%). Demographics of participants were different to what has been reported in literature-there were a lower proportion of type non-small cell lung cancer (NSCLC), a higher proportion of type small cell lung cancer (SCLC), a higher rate of early-stage diagnosis, and a younger population. There were 56% male participants. Although physicians were the main stakeholders influencing treatment choice and quality of life (QoL) discussions, the patient's family/relatives ranked highly as important stakeholders. The top reasons patients reported choosing a treatment were related to efficacy, and hesitation to start a treatment was related to concerns about side effects. QoL was an important factor in both cases. Patients are impacted physically, socially, and mentally-50% report an impact on employment status, 48% report daily difficulties in mental well-being, and 64% have received psychological support or would like to. Disparities were observed across countries in genetic/biomarker testing completed or planned (30-88%) and being asked to participate in clinical trials (15-49%), which reflects the status of how different patient with LC care pathways have adopted innovation in LC care.</p><p><strong>Conclusion: </strong>Both medical and external factors impact experiences and outcomes of patients living with LC, including the role of family in treatment and QoL discussions. There are intercountry differences in knowledge and disease management.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":"145-164"},"PeriodicalIF":3.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11880444/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142855966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aggressive Subtypes of Laryngeal Chondrosarcoma and their Clinical Behavior: A Systematic Review.","authors":"Cesare Piazza, Claudia Montenegro, Michele Tomasoni, Ilmo Leivo, Göran Stenman, Abbas Agaimy, Roderick H W Simpson, Nina Zidar, Alfio Ferlito","doi":"10.1007/s40487-024-00323-1","DOIUrl":"10.1007/s40487-024-00323-1","url":null,"abstract":"<p><strong>Introduction: </strong>Laryngeal chondrosarcoma (CS) is a rare indolent malignant tumor. High-grade (G3), dedifferentiated (DD), and myxoid (MY) CSs are considered more aggressive subtypes due to their metastatic potential and relatively poor outcomes. The aim of this systematic review is to evaluate treatment modalities and survival outcomes in patients affected by these rarer CS subtypes.</p><p><strong>Methods: </strong>Papers published from January 1, 2000, to August 25, 2024, describing cases of laryngeal G3, DD, and MY CS were included.</p><p><strong>Results: </strong>A total of 38 patients (15 G3, 13 DD, and 10 MY) were selected. Cricoid cartilage was the most common site of origin. Total laryngectomy (TL) was often performed. Primary conservative approaches in 42.8% of patients were followed by loco-regional recurrence.</p><p><strong>Conclusions: </strong>Aggressive subtypes of CS require a radical approach because of the higher rate of loco-regional and distant recurrences compared to low-grade CS. TL with radical intent is the most common treatment, and adjuvant therapy should be considered after careful multidisciplinary discussion.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":"49-67"},"PeriodicalIF":3.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11880495/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142932949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}